熱門資訊> 正文
Centessa股价在ONX 750的第一阶段发作性睡病研究中上涨10%
2024-09-10 23:41
- Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) jumped 10% Tuesday after the company announced positive Phase 1 data for its narcolepsy drug candidate ORX750, with plans to rapidly advance it into Phase 2 testing.
- Centessa said that based on the interim Phase 1 data, it intends to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia beginning in Q4, according to a statement.
More on Centessa Pharmaceuticals
- Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals
- Historical earnings data for Centessa Pharmaceuticals
- Financial information for Centessa Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
